Scientists test new drug timing to outsmart resistant cancers

This early-phase study is testing a new way of giving two cancer drugs—one after the other instead of together—to see if it is safe and tolerable for people with advanced solid tumors that have stopped responding to standard treatments. The trial aims to find the best dose and see if this sequential schedule can shrink or stabilize tumors in patients whose cancer has progressed despite prior therapy, particularly a type called PARP inhibitors. It involves a small group of adults with specific genetic mutations in their tumors.